All Posts

U.S. stocks rebounded Monday, June 8, 2026, led by a sharp recovery in semiconductor and other AI‑linked names after last week’s tech rout, even as investors digested hotter labor data, higher yields, and renewed Middle East tensions.

Market wrap: risk back on, chips lead

• Major indices bounced after Friday’s heavy selling, with the S&P 500 and Nasdaq climbing as chip stocks reversed a portion of last week’s steep losses.
• Intraday, the S&P 500 was up roughly three‑quarters of a percent, the Dow also added a modest gain in early trading but slipped .16% at the close, and the Nasdaq outperformed with gains north of 1% as megacap tech and AI leaders rallied and ended up .86% at the close.

Macro backdrop: strong jobs, stickier Fed, geopolitics

• Friday’s May payrolls report showed robust job creation and a still‑firm labor market, reinforcing the view that the economy remains resilient and pushing markets to price in a higher probability of another Fed hike by year‑end.
• Short‑dated Treasury yields moved higher and the curve flattened further, reflecting expectations that policy will stay restrictive for longer as inflation risks prove stubborn.
• The dollar firmed against major peers, aided by higher U.S. yields and a European Central Bank that appears more constrained on additional tightening.
• In the background, renewed hostilities between Iran and Israel and a fragile ceasefire narrative kept geopolitical risk firmly on the dashboard, even as some headlines pointed to active ceasefire negotiations.

For investors, that mix—strong labor, firm inflation pressures, and geopolitical noise—keeps the “higher‑for‑longer” and “headline‑driven volatility” themes very much alive.

Global and cross‑asset moves

• Asia was the epicenter of stress, with South Korea’s Kospi dropping more than 8% at one point and triggering a temporary halt in trading amid heavy selling in major chip producers and AI‑linked names.
• Japan’s Nikkei and other Asia‑Pacific indices also traded sharply lower as sentiment toward global AI and tech exposure deteriorated following last week’s Nasdaq slide.
• European equities opened weaker, with broad selling across sectors as investors reacted to both the Asia shock and Middle East tension; tech lagged while oil and gas names found some support.
• Crude oil pushed higher moving into the low‑90s as traders balanced ceasefire hopes against the risk of broader regional escalation.

Outside of equities, the broader risk complex reflected a classic late‑cycle pattern: firmer dollar, higher front‑end yields, and commodities responding to geopolitics as much as fundamentals.

Sectors, AI chips, energy, defensives

• Semiconductors were the engine of today’s rebound; names beaten up in Friday’s tech washout—particularly AI‑exposed chipmakers—led the move higher as investors selectively re‑entered the space.
• One chip name getting outsized attention was Marvell (MRVL), which jumped double‑digits during intraday trading as inclusion in the S&P 500 and AI‑driven demand expectations helped it claw back a large chunk of Friday’s losses and closed up +9.63% Monday.
• Other high‑beta chip and memory names, including NVIDIA, Micron, and Intel, posted strong pre‑market and midday gains, reinforcing the narrative that AI infrastructure remains a key secular theme despite tactical drawdowns.
• At the sector level, information technology outperformed by a wide margin, with energy also in the green as higher crude prices supported integrated oils and select E&Ps, while communication services and utilities lagged.

VP Watchlist Updates

Below is an update‑style snapshot on the VP Watchlist names for the week, focused on recent catalysts, positioning, and narrative rather than precise price moves.

Amwell® (AMWL, $8.75, +1.51%)

Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, highlighted (May 18) results from an independently led, National Institute of Mental Health-funded randomized trial published in Nature Human Behaviour examining SilverCloud® by Amwell®, the company’s digital behavioral health solution.

Amwell announced (May 5) financial results for the first quarter ended Mar. 31, 2026. “Entering 2026, Amwell’s main focus was to consolidate our platform to fulfill the unmet needs of our Payer and Provider customers. The Technology-Enabled Care infrastructure we have developed to fill that gap in the market continues to gain traction as customers recognize its clear advantages: lower costs, better outcomes, stronger market share and an increased level of control and agility. Our platform is performing well and built to leverage the latest AI-powered innovations, positioning it as essential infrastructure for tech-enabled care delivery,” said Dr. Ido Schoenberg, Chairman and CEO of Amwell. “We are seeing powerful validation of the platform with significant pipeline growth and a number of meaningful renewals. With this momentum and the favorable regulatory tailwinds, Amwell is well-positioned for continued strong execution this year and to reach our goal of positive cash flow from operations in the fourth quarter.”

Eupraxia Pharmaceuticals (EPRX, $5.99, +.67%)

Eupraxia Pharmaceuticals Inc. (EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (May 5) the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). These data were also presented at the ongoing Digestive Disease Week (“DDW”) conference in Chicago. “The EREFS is an important, validated visual index of severity of EoE disease in the esophagus of patients. It measures edema, rings and strictures and other visible markers of disease often associated with symptoms. Today’s data demonstrated improvement in two key outcomes with EP-104GI in the treatment of EoE: first, that a full injection protocol of 20 injections resulted in more pronounced improvement than a protocol with fewer injections and less coverage area within the esophagus; second, with the higher number of injections, a consistent response in both the inflammatory and fibrotic sub scores of EREFS was observed,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “This EREFS data being reported at DDW is consistent with the improvements we have seen in EoE symptoms and tissue health (EoEHSS) and suggests improvement in inflammation, fibrosis and the associated narrowing of the esophagus.”

Eurpraxia announced on Friday, May 1, the appointment of Dr. Jeymi Tambiah as Chief Medical Officer (CMO) as well as the retirement of Dr. Mark Kowalski, Eupraxia’s current CMO. Dr. Jeymi Tambiah (MB ChB, FRCS, MS, FAPCR, FFPM), is a Board Certified Cardiothoracic Surgeon physician scientist who practiced at Guys and St Thomas’ Hospitals prior to entering the biopharmaceutical industry in 2008. Dr. Tambiah brings over 18 years of experience in clinical development, medical and regulatory strategy, and product commercialization across pharmaceutical and biotechnology organizations.

Eupraxia recently co-hosted a Tribe Public www.TribePublic.com, CEO Presentation & Q&A Webinar event, Wednesday, April 1 titled “Turning EOE Into a Once-a-Year Appointment.” The event featured James A. Helliwell, M.D., Co‑founder and CEO of Eupraxia Pharmaceuticals (NASDAQ: EPRX), who discusses the company’s precision drug‑delivery platform, its approach to Eosinophilic Esophagitis (EoE), and broader pipeline priorities, followed by a focused 5–10 minute Q&A. You may watch it now at this Youtube link.

Modular Medical (MODD, $4.86, +4.74%)

• Modular Medical, Inc. (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery, announced (June 4) the launch of PivotPump.com, a patient-focused website designed to support individuals seeking a simpler path to insulin pump therapy. This launch follows the Company’s receipt of U.S. Food and Drug Administration (“FDA”) clearance in April 2026 for its Pivot™ insulin delivery system. The FDA clearance represents a significant milestone in Modular Medical’s strategy to expand access to insulin pump technology, particularly among individuals historically underserved by existing solutions. The Company remains on track for commercial launch in the fall of 2026. Pivot is designed for people living with diabetes who rely on daily insulin injections, as well as those who have encountered technological, usability, or cost-related barriers with traditional pump systems. The system emphasizes simplicity and ease of use for the patient and full access to clinical information for the clinician to reduce adoption friction. The PivotPump.com website provides accessible, educational content on insulin pump therapy and highlights the Company’s focus on real-world usability and supporting patients in evaluating and adopting pump-based diabetes care.
• On May 1, CEO Jeb Besser join Tribe Public’s members to unpack a simple question with big implications: what happens when an “almost‑pumper” market finally meets an FDA‑cleared device built for the rest of us, not just the superusers? Tribe Public hosted its CEO Presentation and Q&A Webinar, “From FDA Wins to Scaling Manufacturing – What Investors Should Watch,” on Friday, May 1, 2026, at 8:00 a.m. PT / 11:00 a.m. ET. In keeping with Tribe’s reputation for efficient programming, the session ran approximately 30 minutes, pairing a focused prepared talk with a 5–10 minute live Q&A segment that allowed investors to drill into timelines, capital needs, and commercial strategy. Besser’s formal remarks were framed under the title “From FDA Wins to Scaling Manufacturing – What Investors Should Watch,” setting the tone for a discussion that sat at the intersection of regulation, innovation, and recurring‑revenue hardware. By registering, attendees also joined Tribe Public’s membership base, ensuring they will receive future invitations to CEO briefings, sector spotlights, and investor wish‑list events.
• Modular Medical announced (APRIL 19) the pricing of a registered direct offering consisting of 750,000 shares of the Company’s common stock at an offering price of $4.50 per share. The gross proceeds to the Company from the Offering are estimated to be approximately $3.4 million before deducting placement agent fees and other offering expenses. The Offering is expected to close on or about April 21, 2026, subject to the satisfaction of customary closing conditions.
• Modular Medical’s latest regulatory milestone upgrades the narrative: the company has now (April 9) secured FDA 510(k) clearance for its Pivot tubeless insulin patch pump, moving from “launch‑ready” to “launch‑approved” in the heart of the fast‑growing diabesity market. The FDA has cleared Modular Medical’s Pivot patch pump as a tubeless, removable insulin delivery system, formally validating the device’s design and performance for commercial use in U.S. adults living with diabetes. The clearance converts what had been a Q1 2026 launch “subject to FDA response” into a tangible commercial pathway, giving the company permission to sell into an insulin pump market that has been estimated at roughly 8 billion dollars globally. Pivot is engineered as a simplified, two‑part patch pump with a 3‑milliliter removable reservoir, no need for battery recharging, and the ability to bolus without a dedicated controller, aiming squarely at patients who have stayed on multiple daily injections because traditional pumps felt too complex, cumbersome, or costly. By clearing Pivot, the FDA is effectively endorsing Modular Medical’s attempt to make advanced insulin delivery feel less like adopting a gadget and more like upgrading a daily habit.

The InterGroup Corporation (INTG, $32.95, +1.32%)

• The InterGroup Corporation (NASDAQ: INTG) announced financial (May 11) results for the fiscal third quarter ended March 31, 2026. InterGroup is a diversified holding company with interests in hospitality (through its majority‑owned subsidiary Portsmouth Square, Inc.), real estate operations, and investment transactions. The discussion below is derived from the Company’s Quarterly Report on Form 10‑Q for the quarter ended March 31, 2026. Third Quarter Fiscal 2026 Highlights (Three Months Ended March 31, 2026 vs. 2025) are as follows:
  • Total revenues increased to $20.372 million from $16.824 million (+21%).
  • Income from operations increased to $4.260 million from $2.350 million (+81%).
  • GAAP net income was $0.595 million, compared to a GAAP net loss of $0.750 million in the prior‑year quarter.
  • Net income attributable to InterGroup was $0.457 million, or $0.21 per diluted share, compared to a net loss attributable to InterGroup of $0.578 million, or $0.27 per share, in the prior‑year quarter.
  • Hotel revenues increased to $16.497 million from $12.210 million (+35%). For additional context, Hotel revenues for the quarter ended March 31, 2026 exceeded the comparable pre‑pandemic quarter ended March 31, 2019 by approximately $1.028 million.
  • Real estate revenues were $3.875 million compared to $4.614 million in the prior‑year quarter (‑16%).
  • Net loss from investment transactions was $(0.342) million compared to $(1.379) million in the prior‑year quarter.

Nokia (NOK, $14.59,+1.46%)

• Nokia has quietly stitched together a new chapter in its comeback story—one that runs from American living rooms to Pentagon test ranges, and now straight through NVIDIA’s (NVDA) data centers. With NVIDIA’s billion‑dollar vote of confidence in the fall and another blockbuster NVIDIA earnings report due today, the old handset icon is suddenly speaking fluent AI.
• Nokia announced (May 21) the launch of its AI Networking Innovation Lab, a new center designed to drive co-innovation with AI and cloud partners and accelerate the development of next-generation networking technologies for artificial intelligence (AI) infrastructure. Located within Nokia’s Sunnyvale, California facility, the lab serves as an innovation hub where Nokia will work across advanced AI networking technologies, architectures and ecosystems with a variety of partners to help shape the future of data center networking. AI workloads are fundamentally changing how data center networks must operate. The performance, scale, and precision required to support large-scale AI training and distributed, real-time inference place unprecedented demands on networking infrastructure. To address these challenges, Nokia is adopting a new approach to how technologies are integrated, tested, and deployed from the ground up for the AI era.

NVIDIA (NVDA, $208.64, +1.73%)

On Monday, Nvidia (NVDA) announced its new RTX Spark processor for Windows laptops on Monday during its GTC Taipei event. The chip integrates a Grace CPU with a Blackwell GPU and is expected to appear in high-end laptops from manufacturers including Asus, Dell (DELL), HP (HPQ), and Microsoft (MSFT) later this fal

Tigress Financial raised their price target to $425 on May 27 and maintained their ‘Strong Buy’ Rating.

Nvidia’s First Quarter Fiscal 2027 earnings report crossed the tape Wednesday, May 20, and the immediate takeaway is that the AI engine is still running at full throttle, even if Wall Street was already leaning hard on the accelerator. The story today is less about whether Nvidia is growing and more about just how far into “infrastructure of AI” territory it has now ventured.

McDonald’s (MCD, $277.78)

• Morgan Stanley (April 21) has adjusted its price target on McDonald’s (MCD) to $334, maintaining an Equal Weight stance on the stock. The firm’s analyst highlighted consumer strength heading into first-quarter results, noting that earnings quality will likely vary across the restaurant and food distribution landscape . While some operators may face headwinds, the underlying consumer backdrop remains robust, which could support McDonald’s performance as one of the industry’s quality players positioned to navigate the current environment .

Tesla (TSLA, $408.95, +4.59%)

Reuters reported that new registrations of Tesla (TSLA), opens new tab cars rose across several ​European markets in May, continuing a recovery in the U.S. electric vehicle maker’s European sales.

Serina Therapeutics (NYSE: SER, $1.90)

Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, reported (May 14) its financial results for the first quarter ended March 31, 2026, along with key business updates. The company highlighted the follow: Phase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson’s Disease; TFL data from the SAD study arm targeted for first half of 2027 & Closed $21.2 million private placement financing to support continued advancement of SER-252. “With our Phase 1b registrational study of SER-252 now underway and a strengthened balance sheet, Serina is entering an important execution phase as we work toward our first clinical data in patients with advanced Parkinson’s disease,” said Steve Ledger, Chief Executive Officer of Serina. “SER-252 represents the first clinical validation of our POZ Platform™, which is designed to optimize well-understood therapeutics by improving pharmacokinetics, tolerability and dosing profiles. We believe this approach has the potential to unlock meaningful value across multiple modalities, and we are building a pipeline and partnership strategy to fully leverage the breadth of the platform.”

BuzzFeed, Inc. (BZFD, $1.32)

BuzzFeed, Inc. (“BuzzFeed” or the “Company”) (Nasdaq: BZFD) today announced the closing of its previously announced transaction with Allen Family Digital, LLC, an affiliate of Byron Allen’s Family Office, under which Allen Family Digital, LLC acquired approximately 51% of the Company’s outstanding shares. Byron Allen has assumed the role of Chairman and Chief Executive Officer, and Jonah Peretti has transitioned to his newly created role as President of BuzzFeed AI. Under the terms of the agreement, Allen Family Digital acquired 40 million shares of BuzzFeed, Inc. common stock at a price of $3.00 per share, representing a total transaction value of $120 million for a total purchase price of $120 million. The transaction was funded with $20 million in cash at closing and a $100 million promissory note due five years from closing, accruing interest at 5% annually. BuzzFeed has used $12.5 million of the cash proceeds from the transaction to pay down existing indebtedness, materially strengthening the Company’s balance sheet and enhancing financial flexibility to support future growth initiatives. “Jonah is a great visionary and has done a phenomenal job. BuzzFeed and HuffPost have become two iconic global digital media brands with powerful audience reach and strong cultural importance,” said Byron Allen, Chairman and CEO of BuzzFeed. “Our vision is to build on the iconic foundation of BuzzFeed and HuffPost by expanding into free-streaming video, audio and user-generated content. As of this moment, with the power of AI, BuzzFeed is officially chasing YouTube to become another premier free-streaming video service.”

FMC Corporation (NYSE: FMC, $11.10)

FMC Corporation (NYSE: FMC) announced (May 26) that Andrew Sandifer, FMC executive vice president and chief financial officer, will speak at the 16th Annual Wells Fargo Industrials & Materials Conference on June 9, 2026, at 2:15 p.m. Central Time. A live webcast will be available at www.fmc.com/investors.

FMC Corporation (NYSE:FMC) reported (April 29) first quarter 2026 results above guidance with Adjusted EBITDA above high end of range, reaffirms full-year outlook. Their first quarter 2026 revenue of $759 million, down 4 percent versus first quarter 2025. First quarter 2026 revenue, excluding India, was $762 million, down 4 percent versus first quarter 2025, which included India. On a GAAP basis, the company reported a loss of $2.25 per diluted share in the first quarter, a decrease of $2.13 versus first quarter 2025. First quarter adjusted loss per diluted share of $0.23 was down 41 cents versus first quarter 2025. FMC Corporation also announced today that its board of directors declared a regular quarterly dividend of 8 cents per share (roughly 2.26%), payable on July 16, 2026, to shareholders of record as of the close of business on June 30, 2026.

Hudson Pacific Properties, Inc. (NYSE: HPP, $14.60, +6.26%)

Hudson Pacific Properties, Inc. announced ( May 7) financial and operating results for the first quarter 2026. The highlighted: – Executed Over 550,000 Square Feet of Office Leases, Third Consecutive Quarter of Occupancy Gains –– Hollywood Stages 97% Leased, Sunset Pier 94 Stages Reached 100% Leased by Quarter End –– G&A Improved 32% Year-Over-Year, Reflecting Continued Cost Discipline –– $933 Million of Total Liquidity. Victor Coleman, Hudson Pacific’s CEO and Chairman, commented, “Our first quarter results reflect the meaningful progress we’re making to position Hudson Pacific for long-term value creation. We delivered our third consecutive quarter of occupancy gains, executing over 550,000 square feet of office leases, while our Hollywood studio stages reached 97% leased and Sunset Pier 94 achieved 100% leased within its first quarter of operations. We also continued to strengthen our financial foundation, improving G&A by 32% year-over-year, maintaining total liquidity in excess of $930 million, and growing Core FFO sequentially on a per share basis.“

The Sources

[1] S&P 500 closes higher as chips stage a comeback, Iran stops strikes on Israel: Live updates https://www.cnbc.com/2026/06/07/stock-market-today-live-updates.html
[2] Stock Market Live June 8, 2026: S&P 500 (SPY) Rebounds with Chip Stocks https://247wallst.com/investing/2026/06/08/stock-market-live-june-8-2026-sp-500-spy-rebounds-with-chip-stocks/
[3] Stock Market Today: Nasdaq Opens Higher; Oil Rallies After Iran-Israel Trade Strikes — Live Update https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-06-08-2026
[4] The Korean Stock Market Just Crashed Sunday Night But the Nasdaq Is Rising on Monday https://247wallst.com/investing/2026/06/08/the-korean-stock-market-just-crashed-sunday-night-will-the-nasdaq-follow-tomorrow/
[5] Stocks Rebound, Led by Chips, as CPI Data Looms https://www.schwab.com/learn/story/stock-market-update-open
[6] Financial Markets Daily Report 08 June 2026 https://www.caixabankresearch.com/en/publications/financial-markets-daily-report/08-june-2026
[7] Weekly Market Recap – Manulife John Hancock Investments https://www.jhinvestments.com/weekly-market-recap
[8] Weekly Market Recap https://am.jpmorgan.com/content/dam/jpm-am-aem/americas/us/en/insights/market-insights/wmr/weekly_market_recap.pdf
[9] Stock Futures, Dow Jones Futures, Korean Stock Market [LIVE] – 8th June https://coinpedia.org/news/kospi-index-crash-south-korea-stock-market-bloodbath-live-8th-june/
[10] Value Line – Research – Dashboard https://research.valueline.com
[11] MARKET RECAP 📉 The S&P 500 just had its worst day of … https://www.instagram.com/reel/DZN9BNNvcXU/
[12] Yahoo Finance Live: Daily Market Coverage – June 8, 2026 3PM – 5PM (ET) https://www.youtube.com/watch?v=YykkUfFDG-8
[13] Daily market snapshot https://www.edwardjones.com/us-en/market-news-insights/stock-market-news/daily-market-recap
[14] June 2026 Economic and Market Outlook https://www.youtube.com/watch?v=nesXzD4gyU8
[15] Stock Market LIVE Updates: Nifty & Sensex | High Crude Oil … https://www.youtube.com/watch?v=7BblYsOQFj0

U.S. equities finished the week ending June 5, 2026 under pressure, as a hotter‑than‑expected jobs print pushed Treasury yields higher, revived “higher for longer” Fed fears, and triggered profit‑taking in the year’s AI and semiconductor winners, even as select earnings stories like ABM Industries (ABM, $42.52, +6.62%) and CooperCompanies (COO, $67.34, +8.58%) showed resilient micro fundamentals.

Macro backdrop and Fed narrative

The dominant macro story this week was labor‑market resilience colliding with a market priced for easing. A stronger nonfarm payrolls report, with job gains well above consensus and unemployment holding near the mid‑4% range, reinforced the view that the economy remains too firm to justify imminent rate cuts.

Treasury yields moved sharply higher into Friday as traders marked up the probability of additional Fed tightening or at least a longer plateau at restrictive rates. That move in rates pressured duration‑sensitive growth stocks and re‑steepened the narrative that “good news is bad news” for risk assets when the Fed reaction function is center stage.

Equity markets: indices and leadership shifts

Across the major U.S. benchmarks, the tone skewed risk‑off, with all three indices under pressure into week‑end. The S&P 500 (7,383.83, -2.59% over the last 5-days) and Nasdaq (25,709.43, -4.68% over the last 5-days) gave back recent gains as higher yields compressed multiples, while the Dow (50,866.78, -.32% over the last 5-days) held up somewhat better thanks to its tilt toward value, cash flow, and income‑oriented constituents.The small caps on the Russell 2000 closed ar 2,833.50, -2.94% over the last 5-days.

Chip and broader AI‑adjacent growth names saw outsized selling as investors rotated out of crowded winners and reassessed earnings‑duration assumptions in a higher‑rate regime. More defensive and income‑oriented pockets—utilities, select financials, and quality industrials—fared relatively better as investors sought ballast against rate volatility.

Rates, credit, and cross‑asset tone

The move in front‑end and belly Treasury yields was the key cross‑asset signal, with the market repricing away from a benign “Goldilocks” soft‑landing narrative toward something more consistent with sticky growth and persistent inflation risk. Credit markets remained orderly, with spreads widening modestly but not signaling systemic stress, suggesting this week’s move was more about valuation and positioning than a fundamental credit event.

Lower energy prices and still‑benign inflation expectations provided a partial offset, preventing a full‑blown risk‑off cascade and allowing some investors to frame the equity pullback as a valuation reset within an intact earnings cycle. For long‑term allocators, the combination of higher all‑in yields and only modest spread widening kept fixed income attractive as both ballast and carry.

Company highlights: ABM and CooperCompanies

ABM Industries delivered a solid fiscal second quarter, posting record revenue growth in the high‑single‑digit range and reaffirming its full‑year adjusted EPS outlook. The company’s performance underscored the resilience of facilities, engineering, and business services demand even in a choppy macro tape, with management emphasizing execution, cost control, and disciplined capital allocation.

CooperCompanies reported an 8% year‑over‑year increase in fiscal Q2 revenue to just over 1.08 billion dollars, with both its vision‑care and women’s health businesses contributing balanced growth. Non‑GAAP EPS rose meaningfully and beat expectations, but GAAP earnings were dragged into a loss by a substantial litigation‑related charge tied to a prior women’s health product recall, highlighting how idiosyncratic legal overhangs can mask otherwise healthy operating momentum.

VP Watchlist Updates

Below is an update‑style snapshot on the VP Watchlist names for the week, focused on recent catalysts, positioning, and narrative rather than precise price moves.

Amwell® (AMWL, $8.62)

Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, highlighted (May 18) results from an independently led, National Institute of Mental Health-funded randomized trial published in Nature Human Behaviour examining SilverCloud® by Amwell®, the company’s digital behavioral health solution.

Amwell announced (May 5) financial results for the first quarter ended Mar. 31, 2026. “Entering 2026, Amwell’s main focus was to consolidate our platform to fulfill the unmet needs of our Payer and Provider customers. The Technology-Enabled Care infrastructure we have developed to fill that gap in the market continues to gain traction as customers recognize its clear advantages: lower costs, better outcomes, stronger market share and an increased level of control and agility. Our platform is performing well and built to leverage the latest AI-powered innovations, positioning it as essential infrastructure for tech-enabled care delivery,” said Dr. Ido Schoenberg, Chairman and CEO of Amwell. “We are seeing powerful validation of the platform with significant pipeline growth and a number of meaningful renewals. With this momentum and the favorable regulatory tailwinds, Amwell is well-positioned for continued strong execution this year and to reach our goal of positive cash flow from operations in the fourth quarter.”

Eupraxia Pharmaceuticals (EPRX, $5.95)

Eupraxia Pharmaceuticals Inc. (EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (May 5) the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). These data were also presented at the ongoing Digestive Disease Week (“DDW”) conference in Chicago. “The EREFS is an important, validated visual index of severity of EoE disease in the esophagus of patients. It measures edema, rings and strictures and other visible markers of disease often associated with symptoms. Today’s data demonstrated improvement in two key outcomes with EP-104GI in the treatment of EoE: first, that a full injection protocol of 20 injections resulted in more pronounced improvement than a protocol with fewer injections and less coverage area within the esophagus; second, with the higher number of injections, a consistent response in both the inflammatory and fibrotic sub scores of EREFS was observed,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “This EREFS data being reported at DDW is consistent with the improvements we have seen in EoE symptoms and tissue health (EoEHSS) and suggests improvement in inflammation, fibrosis and the associated narrowing of the esophagus.”

Eurpraxia announced on Friday, May 1, the appointment of Dr. Jeymi Tambiah as Chief Medical Officer (CMO) as well as the retirement of Dr. Mark Kowalski, Eupraxia’s current CMO. Dr. Jeymi Tambiah (MB ChB, FRCS, MS, FAPCR, FFPM), is a Board Certified Cardiothoracic Surgeon physician scientist who practiced at Guys and St Thomas’ Hospitals prior to entering the biopharmaceutical industry in 2008. Dr. Tambiah brings over 18 years of experience in clinical development, medical and regulatory strategy, and product commercialization across pharmaceutical and biotechnology organizations.

Eupraxia recently co-hosted a Tribe Public www.TribePublic.com, CEO Presentation & Q&A Webinar event, Wednesday, April 1 titled “Turning EOE Into a Once-a-Year Appointment.” The event featured James A. Helliwell, M.D., Co‑founder and CEO of Eupraxia Pharmaceuticals (NASDAQ: EPRX), who discusses the company’s precision drug‑delivery platform, its approach to Eosinophilic Esophagitis (EoE), and broader pipeline priorities, followed by a focused 5–10 minute Q&A. You may watch it now at this Youtube link.

Modular Medical (MODD, $4.6399)

• Modular Medical, Inc. (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery, announced (June 4) the launch of PivotPump.com, a patient-focused website designed to support individuals seeking a simpler path to insulin pump therapy. This launch follows the Company’s receipt of U.S. Food and Drug Administration (“FDA”) clearance in April 2026 for its Pivot™ insulin delivery system. The FDA clearance represents a significant milestone in Modular Medical’s strategy to expand access to insulin pump technology, particularly among individuals historically underserved by existing solutions. The Company remains on track for commercial launch in the fall of 2026. Pivot is designed for people living with diabetes who rely on daily insulin injections, as well as those who have encountered technological, usability, or cost-related barriers with traditional pump systems. The system emphasizes simplicity and ease of use for the patient and full access to clinical information for the clinician to reduce adoption friction. The PivotPump.com website provides accessible, educational content on insulin pump therapy and highlights the Company’s focus on real-world usability and supporting patients in evaluating and adopting pump-based diabetes care.
• On May 1, CEO Jeb Besser join Tribe Public’s members to unpack a simple question with big implications: what happens when an “almost‑pumper” market finally meets an FDA‑cleared device built for the rest of us, not just the superusers? Tribe Public hosted its CEO Presentation and Q&A Webinar, “From FDA Wins to Scaling Manufacturing – What Investors Should Watch,” on Friday, May 1, 2026, at 8:00 a.m. PT / 11:00 a.m. ET. In keeping with Tribe’s reputation for efficient programming, the session ran approximately 30 minutes, pairing a focused prepared talk with a 5–10 minute live Q&A segment that allowed investors to drill into timelines, capital needs, and commercial strategy. Besser’s formal remarks were framed under the title “From FDA Wins to Scaling Manufacturing – What Investors Should Watch,” setting the tone for a discussion that sat at the intersection of regulation, innovation, and recurring‑revenue hardware. By registering, attendees also joined Tribe Public’s membership base, ensuring they will receive future invitations to CEO briefings, sector spotlights, and investor wish‑list events.
• Modular Medical announced (APRIL 19) the pricing of a registered direct offering consisting of 750,000 shares of the Company’s common stock at an offering price of $4.50 per share. The gross proceeds to the Company from the Offering are estimated to be approximately $3.4 million before deducting placement agent fees and other offering expenses. The Offering is expected to close on or about April 21, 2026, subject to the satisfaction of customary closing conditions.
• Modular Medical’s latest regulatory milestone upgrades the narrative: the company has now (April 9) secured FDA 510(k) clearance for its Pivot tubeless insulin patch pump, moving from “launch‑ready” to “launch‑approved” in the heart of the fast‑growing diabesity market. The FDA has cleared Modular Medical’s Pivot patch pump as a tubeless, removable insulin delivery system, formally validating the device’s design and performance for commercial use in U.S. adults living with diabetes. The clearance converts what had been a Q1 2026 launch “subject to FDA response” into a tangible commercial pathway, giving the company permission to sell into an insulin pump market that has been estimated at roughly 8 billion dollars globally. Pivot is engineered as a simplified, two‑part patch pump with a 3‑milliliter removable reservoir, no need for battery recharging, and the ability to bolus without a dedicated controller, aiming squarely at patients who have stayed on multiple daily injections because traditional pumps felt too complex, cumbersome, or costly. By clearing Pivot, the FDA is effectively endorsing Modular Medical’s attempt to make advanced insulin delivery feel less like adopting a gadget and more like upgrading a daily habit.

The InterGroup Corporation (INTG, $32.52)

• The InterGroup Corporation (NASDAQ: INTG) announced financial (May 11) results for the fiscal third quarter ended March 31, 2026. InterGroup is a diversified holding company with interests in hospitality (through its majority‑owned subsidiary Portsmouth Square, Inc.), real estate operations, and investment transactions. The discussion below is derived from the Company’s Quarterly Report on Form 10‑Q for the quarter ended March 31, 2026. Third Quarter Fiscal 2026 Highlights (Three Months Ended March 31, 2026 vs. 2025) are as follows:
  • Total revenues increased to $20.372 million from $16.824 million (+21%).
  • Income from operations increased to $4.260 million from $2.350 million (+81%).
  • GAAP net income was $0.595 million, compared to a GAAP net loss of $0.750 million in the prior‑year quarter.
  • Net income attributable to InterGroup was $0.457 million, or $0.21 per diluted share, compared to a net loss attributable to InterGroup of $0.578 million, or $0.27 per share, in the prior‑year quarter.
  • Hotel revenues increased to $16.497 million from $12.210 million (+35%). For additional context, Hotel revenues for the quarter ended March 31, 2026 exceeded the comparable pre‑pandemic quarter ended March 31, 2019 by approximately $1.028 million.
  • Real estate revenues were $3.875 million compared to $4.614 million in the prior‑year quarter (‑16%).
  • Net loss from investment transactions was $(0.342) million compared to $(1.379) million in the prior‑year quarter.

Volato Group, Inc. (SOAR, +114.71% over the last 5-days) & M2i Global, Inc. (MTWO)

• M2i Global, Inc, a company specializing in the development and execution of a complete global value supply chain for critical minerals, under Definitive Agreement to merge with Volato Group, Inc. (“Volato”) (NYSE American: SOAR), a technology-driven company, provided (June 3) the following price update to its previously announced agreement for 88,000 tons of copper sourced from Australia. The 88,000 tons of copper is now valued at $1.172 billion, based on today’s price of $13,320 per ton of copper, an increase of over 24% since the agreement was disclosed in July 2024 at $945 million.
• In addition, M2i Global is in due diligence on a number of domestic deposits and is looking to expand its portfolio of projects.
• Prices on the London Metal Exchange climbed as high as $13,320 a ton Tuesday — within striking distance of the all-time high of $14,527 set in January. The move comes despite a fragile geopolitical backdrop, as the ongoing Iran conflict continues to cloud the global growth outlook. Copper is up roughly 10% year-to-date, a run that few pre
• M2i Global, Inc. announced (June 1) the execution of a Letter of Intent (“LOI”) with Aurica Tokenization, Inc. (“Aurica”), a Nevada-domiciled commodity-tokenization company focused on physically-backed gold and strategic-mineral tokens.
• Volato Group, Inc. (NYSE American: SOAR) announced (May 18) that its pro-forma cash balance was $5.5 million at March 31, 2026. This pro-forma cash balance equates to $0.14 cash per share. The pro-forma calculation includes cash raised in April from its now completed ATM Prospectus Supplement filed on March 30, 2026.
• Volato Group, Inc. (NYSE American: SOAR) recently announced voting results indicate that the shareholders have approved the previously announced merger with M2i Global, Inc. (“M2i Global”)(OTCQB: MTWO) with 99% of the shares of common stock present or represented by valid proxy at the special meeting voting in favor of the merger. This marks a significant milestone toward closing the transaction and advancing Volato’s strategic expansion into the critical minerals sector. The number of shares of common stock present or represented by valid proxy at the special meeting was 15.1 million, representing approximately 40% of the total number of shares of common stock entitled to vote. Management believes that the approval reflects strong shareholder alignment with the Company’s strategic direction and long-term growth plans.

Nokia (NOK, $14.38)

• Nokia has quietly stitched together a new chapter in its comeback story—one that runs from American living rooms to Pentagon test ranges, and now straight through NVIDIA’s (NVDA) data centers. With NVIDIA’s billion‑dollar vote of confidence in the fall and another blockbuster NVIDIA earnings report due today, the old handset icon is suddenly speaking fluent AI.
• Nokia announced (May 21) the launch of its AI Networking Innovation Lab, a new center designed to drive co-innovation with AI and cloud partners and accelerate the development of next-generation networking technologies for artificial intelligence (AI) infrastructure. Located within Nokia’s Sunnyvale, California facility, the lab serves as an innovation hub where Nokia will work across advanced AI networking technologies, architectures and ecosystems with a variety of partners to help shape the future of data center networking. AI workloads are fundamentally changing how data center networks must operate. The performance, scale, and precision required to support large-scale AI training and distributed, real-time inference place unprecedented demands on networking infrastructure. To address these challenges, Nokia is adopting a new approach to how technologies are integrated, tested, and deployed from the ground up for the AI era.

NVIDIA (NVDA, $205.10)

On Monday, Nvidia (NVDA) announced its new RTX Spark processor for Windows laptops on Monday during its GTC Taipei event. The chip integrates a Grace CPU with a Blackwell GPU and is expected to appear in high-end laptops from manufacturers including Asus, Dell (DELL), HP (HPQ), and Microsoft (MSFT) later this fal

Tigress Financial raised their price target to $425 on May 27 and maintained their ‘Strong Buy’ Rating.

Nvidia’s First Quarter Fiscal 2027 earnings report crossed the tape Wednesday, May 20, and the immediate takeaway is that the AI engine is still running at full throttle, even if Wall Street was already leaning hard on the accelerator. The story today is less about whether Nvidia is growing and more about just how far into “infrastructure of AI” territory it has now ventured.

McDonald’s (MCD, $279.84, +.23% over the last 5-days)

• Morgan Stanley (April 21) has adjusted its price target on McDonald’s (MCD) to $334, maintaining an Equal Weight stance on the stock. The firm’s analyst highlighted consumer strength heading into first-quarter results, noting that earnings quality will likely vary across the restaurant and food distribution landscape . While some operators may face headwinds, the underlying consumer backdrop remains robust, which could support McDonald’s performance as one of the industry’s quality players positioned to navigate the current environment .

Tesla (TSLA, $391.00)

Reuters reported that new registrations of Tesla (TSLA), opens new tab cars rose across several ​European markets in May, continuing a recovery in the U.S. electric vehicle maker’s European sales.

Serina Therapeutics (NYSE: SER, $1.88, +2.17% over the last 5-days)

Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, reported (May 14) its financial results for the first quarter ended March 31, 2026, along with key business updates. The company highlighted the follow: Phase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson’s Disease; TFL data from the SAD study arm targeted for first half of 2027 & Closed $21.2 million private placement financing to support continued advancement of SER-252. “With our Phase 1b registrational study of SER-252 now underway and a strengthened balance sheet, Serina is entering an important execution phase as we work toward our first clinical data in patients with advanced Parkinson’s disease,” said Steve Ledger, Chief Executive Officer of Serina. “SER-252 represents the first clinical validation of our POZ Platform™, which is designed to optimize well-understood therapeutics by improving pharmacokinetics, tolerability and dosing profiles. We believe this approach has the potential to unlock meaningful value across multiple modalities, and we are building a pipeline and partnership strategy to fully leverage the breadth of the platform.”

BuzzFeed, Inc. (BZFD, $1.40)

BuzzFeed, Inc. (“BuzzFeed” or the “Company”) (Nasdaq: BZFD) today announced the closing of its previously announced transaction with Allen Family Digital, LLC, an affiliate of Byron Allen’s Family Office, under which Allen Family Digital, LLC acquired approximately 51% of the Company’s outstanding shares. Byron Allen has assumed the role of Chairman and Chief Executive Officer, and Jonah Peretti has transitioned to his newly created role as President of BuzzFeed AI. Under the terms of the agreement, Allen Family Digital acquired 40 million shares of BuzzFeed, Inc. common stock at a price of $3.00 per share, representing a total transaction value of $120 million for a total purchase price of $120 million. The transaction was funded with $20 million in cash at closing and a $100 million promissory note due five years from closing, accruing interest at 5% annually. BuzzFeed has used $12.5 million of the cash proceeds from the transaction to pay down existing indebtedness, materially strengthening the Company’s balance sheet and enhancing financial flexibility to support future growth initiatives. “Jonah is a great visionary and has done a phenomenal job. BuzzFeed and HuffPost have become two iconic global digital media brands with powerful audience reach and strong cultural importance,” said Byron Allen, Chairman and CEO of BuzzFeed. “Our vision is to build on the iconic foundation of BuzzFeed and HuffPost by expanding into free-streaming video, audio and user-generated content. As of this moment, with the power of AI, BuzzFeed is officially chasing YouTube to become another premier free-streaming video service.”

FMC Corporation (NYSE: FMC, $11.64)

FMC Corporation (NYSE: FMC) announced (May 26) that Andrew Sandifer, FMC executive vice president and chief financial officer, will speak at the 16th Annual Wells Fargo Industrials & Materials Conference on June 9, 2026, at 2:15 p.m. Central Time. A live webcast will be available at www.fmc.com/investors.

FMC Corporation (NYSE:FMC) reported (April 29) first quarter 2026 results above guidance with Adjusted EBITDA above high end of range, reaffirms full-year outlook. Their first quarter 2026 revenue of $759 million, down 4 percent versus first quarter 2025. First quarter 2026 revenue, excluding India, was $762 million, down 4 percent versus first quarter 2025, which included India. On a GAAP basis, the company reported a loss of $2.25 per diluted share in the first quarter, a decrease of $2.13 versus first quarter 2025. First quarter adjusted loss per diluted share of $0.23 was down 41 cents versus first quarter 2025. FMC Corporation also announced today that its board of directors declared a regular quarterly dividend of 8 cents per share (roughly 2.26%), payable on July 16, 2026, to shareholders of record as of the close of business on June 30, 2026.

Hudson Pacific Properties, Inc. (NYSE: HPP, $13.74, +14.69% over the last 5-days)

Hudson Pacific Properties, Inc. announced ( May 7) financial and operating results for the first quarter 2026. The highlighted: – Executed Over 550,000 Square Feet of Office Leases, Third Consecutive Quarter of Occupancy Gains –– Hollywood Stages 97% Leased, Sunset Pier 94 Stages Reached 100% Leased by Quarter End –– G&A Improved 32% Year-Over-Year, Reflecting Continued Cost Discipline –– $933 Million of Total Liquidity. Victor Coleman, Hudson Pacific’s CEO and Chairman, commented, “Our first quarter results reflect the meaningful progress we’re making to position Hudson Pacific for long-term value creation. We delivered our third consecutive quarter of occupancy gains, executing over 550,000 square feet of office leases, while our Hollywood studio stages reached 97% leased and Sunset Pier 94 achieved 100% leased within its first quarter of operations. We also continued to strengthen our financial foundation, improving G&A by 32% year-over-year, maintaining total liquidity in excess of $930 million, and growing Core FFO sequentially on a per share basis.“

The Sources

1. Yahoo Finance – “Dow, S&P 500, Nasdaq sink as jobs report fuels Fed hike bets, chip stocks sell off”
   https://finance.yahoo.com/markets/live/stock-market-today-dow-sp-500-nasdaq-sink-as-jobs-report-fuels-fed-hike-bets-chip-stocks-sell-off-230134285.html
2. CNBC – “Stock market today – live updates” (June 4, 2026)
   https://www.cnbc.com/2026/06/04/stock-market-today-live-updates.html
3. Yahoo Finance – “ABM reports fiscal second quarter 2026 results”
   https://finance.yahoo.com/markets/stocks/articles/abm-reports-fiscal-second-quarter-105800312.html
4. Yahoo Finance – “CooperCompanies announces second quarter 2026 results”
   https://finance.yahoo.com/sectors/healthcare/articles/coopercompanies-announces-second-quarter-2026-201500956.html
5. ABM Industries – Investor Relations, earnings release archive (for verification and supplemental detail)
   https://investor.abm.com/investor-relations
6. CooperCompanies – Investor Relations, earnings and filings (for verification and supplemental detail)
   https://investor.coopercos.com